ONTX - Onconova Therapeutics GAAP EPS of -$0.26 misses by $0.05 revenue of $0.06M misses by $0.01M
- Onconova Therapeutics press release ( NASDAQ: ONTX ): Q3 GAAP EPS of -$0.26 misses by $0.05 .
- Revenue of $0.06M (flat Y/Y) misses by $0.01M .
- Cash and cash equivalents as of September 30, 2022 were $42.6 million compared with $55.1 million as of December 31, 2021.
- The Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations into 2024.
- Shares -3.41% .
For further details see:
Onconova Therapeutics GAAP EPS of -$0.26 misses by $0.05, revenue of $0.06M misses by $0.01M